Fred Hutchinson Cancer Center: Graft vs Host Disease trials

The registry lists 28 Graft vs Host Disease studies with Fred Hutchinson Cancer Center as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 8Phase 2 23Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Glasdegib for Chronic Graft-Versus-Host DiseaseTerminatedNCT04111497Phase 1/2Results posted
• Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host DiseaseCompletedNCT02513498Phase 2Results posted
• Carfilzomib in Treating Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT02491359Phase 2Results posted
• Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host DiseaseCompletedNCT01616056Phase 2Results posted
• Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)CompletedNCT01523821Phase 1/2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host DiseaseCompletedNCT00929695Phase 3Results posted
• Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDTerminatedNCT00914940Phase 2Results posted
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesTerminatedNCT00450983Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
• Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior TreatmentCompletedNCT00079183Phase 2Results posted
• Tocilizumab for Chronic Graft-versus-Host Disease TreatmentWithdrawnNCT02174263Phase 2
• Chronic GVHD Response Measures ValidationActive, not recruitingNCT01902576
• Immune Mediated Disorders After Allogeneic Hematopoietic Cell TransplantationCompletedNCT01206309
• Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
• Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
• Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell TransplantCompletedNCT00357084Phase 2
• Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerCompletedNCT00346359Phase 2
• Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerCompletedNCT00248430Phase 1/2
• Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderCompletedNCT00054340Phase 1/2
• Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host DiseaseStatus unknownNCT00032279Phase 2
• Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or ColonCompletedNCT00010283Phase 1/2
• Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow TransplantWithdrawnNCT00002790Phase 1/2
• Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow TransplantationCompletedNCT00002456Phase 3